House Oversight Committee Democrats Request Subpoena of Valeant Pharma (VRX)

Valeant Pharmaceuticals (VRX) Subpoena 'Far from Certain', UBS Says; Sees Bounce Back in Stock

UBS analyst Marc Goodman reiterated a Buy rating and $285 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's sell-off amid news Democratic members of the House Committee on Oversight and Govt Reform sent a letter requesting Chairman Jason Chaffetz (Republican) to subpoena Valeant to turn over documents related to price increases for these products.

Goodman notes that, importantly,... More

Fear and Uncertainty Creates Buying Opportunity in Valeant (VRX) - BMO Capital

BMO Capital analyst Alex Arfaei has come out to defend Valeant Pharmaceuticals (NYSE: VRX) which has been under pressure amid the political backlash over soaring drug prices, including yesterday's request for a subpoena from all 18 Democratic... More

Citron Research Negative on Valeant Pharma (VRX); Sees Stock Dropping to $130

(Updated - September 28, 2015 1:52 PM EDT)

Citron Research put a $130 price target on Valeant Pharma (NYSE: VRX), saying Congress should get their subpoena.

The comments from Citron follows news earlier that House democrats are seeking a subpoena related to drug price increases and political rhetoric that they are "price... More

Valeant Pharma (VRX) Bounces Off Lows; Remains Down 12%

Valeant Pharma (NYSE: VRX) has sharply bounced off the lows but remains down 12%. Shares were down as much as 20% earlier following news house democrats are seeking an subpoena related to high drug prices.

Democrats' Letter to Committee on Oversight Related to Valeant Pharmaceuticals (VRX)

(Updated - September 28, 2015 12:59 PM EDT)

Democrats' Letter to Committee on Oversight Related to Valeant Pharmaceuticals (NYSE: VRX).

Biotech ETF (IBB) Sinks Further as House Democrats Seek to Subpoena Valeant (VRX) on Drug Prices

iShares Nasdaq Biotechnology (NASDAQ: IBB) is moving to the lows following headlines the House oversight committee Democrats request subpoena for Valeant Pharma (NYSE: VRX), according to Bloomberg.

This likely has to do with the "price gouging" claim recently made by Presidential hopeful Hillary Clinton.

IBB is down 5.5% to $293.16.

House Oversight Committee Democrats Request Subpoena of Valeant Pharma (VRX)

(Updated - September 28, 2015 1:14 PM EDT)

House oversight committee Democrats have requested a subpoena of Valeant Pharmaceuticals (NYSE: VRX) to turn over documents related to the price increases earlier this year of two heart drugs, Isuprel and Nitropress.

The action follows the recent... More

Valeant Pharma (VRX) Mentioned Cautiously in Blog

Valeant Pharma (NYSE: VRX) was mentioned cautiously in a blog post on Seeking Alpha (link).

Valeant Pharma (VRX) Updates on Recent Stock Price Action; Refutes Media Speculation

On September 28, 2015, Valeant Pharma (NYSE: VRX) distributed a letter to its employees relating to recent changes in Valeants stock price.

Dear Colleagues:

A number of you have asked me and other senior members of our management team about the significant drop in our stock price especially over the past 5 trading days. While the entire pharmaceutical and biotech sector has been impacted by market... More